CDR

164 - Diagnosing, preventing, & treating Alzheimer’s disease, & life lessons from dementia patients

Peter Attia MD

A primary endpoint measure for Alzheimer's drug trials, which involves a subjective interview and rating based on patient and informant reports across six dimensions (e.g., memory, judgment, hobbies).